跳转至内容
Merck
CN

L1764

Sigma-Aldrich

(±)-Lorazepam

别名:

7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C15H10Cl2N2O2
化学文摘社编号:
846-49-1
分子量:
321.16
EC 号:
212-687-6
MDL编号:
MFCD00063406
UNSPSC代码:
12352200
PubChem化学物质编号:
24896291
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

200

药品控制

USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet

创始人

Baxter

SMILES字符串

OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O

InChI

1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

InChI key

DIWRORZWFLOCLC-UHFFFAOYSA-N

基因信息

human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), GABRD(2563), GABRE(2564), GABRG1(2565), GABRG2(2566), GABRG3(2567), GABRP(2568), GABRQ(55879)

正在寻找类似产品? 访问 产品对比指南

相关类别

生化/生理作用

Anxiolytic; ligand for the GABAA receptor benzodiazepine modulatory site.

特点和优势

This compound was developed by Baxter. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Health hazard
GHS08

警示用语：

Warning

危险声明

H361d

危险分类

Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000271056
0000271056
127F08281
127F0828
035F0115

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

S Korkmaz et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 8(3), 175-181 (1998-08-26)
Rats were treated with lorazepam for four days (six times 2 mg kg(-1)) at the ages of 71, 118, 163 and 210 days. Increased excitation (physical dependence) in the withdrawal period was tested several times during 14 days with hexobarbital
A 59-year-old woman who is awake yet unresponsive and stuporous after liver transplantation.
Insung Chung et al.
Chest, 143(4), 1163-1165 (2013-04-03)
David W Loring et al.
Epilepsy & behavior : E&B, 25(3), 329-333 (2012-10-30)
A double-blind, placebo-controlled, crossover design was employed to determine whether acute lorazepam (2 mg orally) cognitive side effects would emerge in a differential age-dependent fashion in 15 young (mean age=22 years) and 12 older (mean age=64 years) subjects. Acute use
Feridun Bülbül et al.
The journal of ECT, 29(1), e1-e1 (2013-02-21)
Despite having been previously associated with schizophrenia, catatonia is more often associated with mood disorders and factors related to general medical conditions. Benzodiazepines are recommended as the first option in treatment of catatonia. For patients who do not sufficiently respond
Catatonic schizophrenia with cavum septum pellucidum.
Janardhanan C Narayanaswamy et al.
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E33-E33 (2012-10-06)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持